Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.

ABSTRACT:

Background

Biomarkers are urgently needed to dissect the heterogeneity of prostate cancer between patients to improve treatment and accelerate drug development. We analysed blood mRNA expression arrays to identify patients with metastatic castration-resistant prostate cancer with poorer outcome.

Methods

Whole blood was collected into PAXgene tubes from patients with castration-resistant prostate cancer and patients with prostate cancer selected for active surveillance. In stage I (derivation set), patients with castration-resistant prostate cancer were used as cases and patients under active surveillance were used as controls. These patients were recruited from The Royal Marsden Hospital NHS Foundation Trust (Sutton, UK) and The Beatson West of Scotland Cancer Centre (Glasgo

SUBMITTER: Olmos D 

PROVIDER: S-EPMC4878433 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature